Khaitan & Co advised Alembic in relation to acquisition of balance 40% stake in Aleor

Khaitan & Co advised Alembic in relation to acquisition of balance 40% stake in Aleor, a joint venture company of Alembic and Orbicular Pharmaceutical Technologies Private Limited, thereby making Aleor a wholly owned subsidiary of Alembic.

NO HEADINGS                                          DETAILS
1. Sector Pharmaceuticals – Dermaceuticals
2. Announcement Date 29 March 2022 (Stock Exchange disclosure of Alembic Pharmaceuticals Limited)

 

3. Execution Date 28 March 2022 (Share Purchase Agreement)
4. Completion Date 29 March 2022
5. Name of Client Alembic Pharmaceuticals Limited (“Alembic”)

 

6. Target, Target Country Aleor Dermaceuticals Limited, India

 

7. Target Description Aleor Dermaceuticals Limited (“Aleor”) is engaged in the business of developing, manufacturing and selling of pharmaceutical (dermatology) products for global markets has product offerings across cream, gel, ointment, shampoo, lotion, solutions, sprays, foams, microsponge and nanoparticulate platform-based products.
8. Deal Description Advised Alembic in relation to acquisition of balance 40% stake in Aleor, a joint venture company of Alembic and Orbicular Pharmaceutical Technologies Private Limited, thereby making Aleor a wholly owned subsidiary of Alembic.
9. Total Consideration Confidential

 

10. Team Members The core deal team comprised of Bhavik Narsana (Partner) and Rutvi Shrimankar (Senior Associate)
11. Role of Firm Advised Alembic in relation to the drafting, reviewing, negotiating, and finalizing various transaction documents and generally advising on various legal issues.
12. Press coverage Stock Exchange Disclosure

 

Alembic Pharma buys out partner stake in Aleor Dermaceuticals | The Economic Times

 

Alembic Pharma acquires 100% stake in Aleor Dermaceuticals | moneycontrol

Join the discussion

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.